Ne
No verificado

Neurogene Inc.

Sobre qué escribimos

BiotecnologíaCienciaFarmacéuticaMedicina - VariosSalud
08/06/2026
Salud
Biotecnología
Medicina - Varios
Farmacéutica
Industria
Neurogene Announces Successful Completion of Dosing in Embolden™ Registrational Trial of NGN-401 for Rett Syndrome
1.00
02/06/2026
Mercado de valores
Ciencia
Biotecnología
Farmacéutica
Salud
Medicina - Varios
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1.00
12/05/2026
Mercado de valores
Eventos
Salud
Biotecnología
Medicina - Varios
Farmacéutica
Neurogene Reports First Quarter 2026 Financial Results and Highlights Recent Updates
1.00
12/05/2026
Eventos
Industria
Ciencia
Medicina - Varios
Biotecnología
Salud
Farmacéutica
Neurogene Highlights Data at ASGCT Meeting Supporting Therapeutic Rationale for ICV Delivery Method in CNS-targeted Gene Therapy
1.00
06/05/2026
Mercado de valores
Ciencia
Biotecnología
Farmacéutica
Salud
Medicina - Varios
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1.00
28/04/2026
Eventos
Ciencia
Biotecnología
Farmacéutica
Salud
Medicina - Varios
Neurogene Announces Upcoming Presentation on the Therapeutic Rationale for ICV Delivery in CNS-Targeted Gene Therapy
1.00
20/04/2026
Mercado laboral
Salud
Biotecnología
Medicina - Varios
Farmacéutica
Neurogene Appoints Christy Shafer as Chief Commercial Officer and Christine Mikail, J.D., to Board of Directors
1.00
08/04/2026
Mercado de valores
Finanzas
Salud
Biotecnología
Medicina - Varios
Farmacéutica
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1.00
24/03/2026
Web y redes sociales
Telefonía
Mercado de valores
Salud
Higiene alimentaria
Biotecnología
Medicina - Varios
Farmacéutica
Neurogene Reports Full Year 2025 Financial Results and Highlights Recent Updates
1.00
11/03/2026
Eventos
Web y redes sociales
Salud
Biotecnología
Ciencia
Farmacéutica
Neurogene to Participate in Stifel 2026 Virtual CNS Forum
1.00

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0